The company provides technology solutions and clinical research services for the life sciences and supply chain industries, recently pivoting toward AI-driven healthcare diagnostics and digital health platforms.
The company lacks a durable moat as evidenced by a 45% revenue decline and persistent negative returns on capital. While it claims domain expertise in life sciences, the recent pivot to AI-driven health apps and 'one-minute clinics' appears speculative and has yet to demonstrate any competitive advantage or pricing power in the financials.
The track record is poor, characterized by the divestment of core assets to settle debt and statutory dues. Recent allocation involves small-scale 'innovation funds' and speculative AI pivots while the company struggles with basic solvency and negative net margins.
Five years out, the speculative pivot into AI-driven health apps failed to gain traction against entrenched tech giants, leaving the company with no viable product and an empty treasury. The 'one-minute clinics' never scaled beyond pilot phases as the firm lacked the capital to compete. Ultimately, the material uncertainty regarding its status as a going concern resolved in the negative; the inability to settle mounting statutory dues and the lack of a functional finance department led to a total cessation of operations and a delisting from the exchange.
RichFakir rates Take Ltd's business quality as poor — 12/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Take Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →